AndroGel Cost in Connecticut 2026: Cash Price, Insurance, Medicaid, and Compounded Alternatives

What Is the Cash Price of AndroGel in Connecticut in 2026?

The retail cash price for a 30-day supply of AndroGel 1.62% at Connecticut pharmacies sits at approximately $510 in 2026, matching AbbVie's published manufacturer list price. Without any discount program or insurance, most Connecticut patients pay close to that figure at CVS, Walgreens, Rite Aid, and independent pharmacies across the state.

Brand-name testosterone gel has seen only modest list-price movement over the past three years. GoodRx and SingleCare negotiated prices can bring that figure down to roughly $400 to $460 at some Connecticut zip codes, but these still represent a substantial monthly expense for most patients.

AndroGel comes in two concentrations: 1% (packets and pump) and 1.62% (pump only). The 1.62% formulation is more commonly prescribed today because it delivers the target dose in a smaller volume, reducing transfer risk to partners and children. The FDA approved AndroGel 1.62% for adult male hypogonadism, defined as a morning serum testosterone consistently below 300 ng/dL confirmed on two separate measurements.

Testosterone deficiency affects an estimated 2.1% of men aged 40 to 79 [1], and documented hypogonadism is the required clinical threshold for prescribing and insurance coverage in Connecticut.

Does Connecticut Medicaid Cover AndroGel?

Connecticut Medicaid (HUSKY Health) covers AndroGel with prior authorization for male hypogonadism. The patient's prescriber must submit documentation showing two morning serum testosterone levels below the laboratory's reference range, typically <300 ng/dL, along with clinical symptoms consistent with hypogonadism such as fatigue, decreased libido, or loss of muscle mass [2].

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy states: "We recommend making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone deficiency and unequivocally low serum testosterone concentrations." [2] Connecticut Medicaid's prior authorization criteria align closely with that language.

Once approved, HUSKY Health will generally cover a 30-day supply at standard pharmacy copay rates (often $3 to $8 for generic-tier drugs, though brand-name AndroGel typically falls on a higher formulary tier). If the prior authorization is denied, the patient or prescriber may appeal within 30 days of the denial notice. Connecticut Medicaid's formulary is updated quarterly, so verifying current tier status through the DXC Technology portal before submitting a PA is advisable.

Patients on HUSKY Health who are denied brand-name AndroGel may qualify for compounded testosterone gel through a 503A pharmacy at no additional cost if their prescriber documents a clinical reason why commercial preparations are unsuitable, though this pathway requires additional documentation [3].

Which Private Insurance Plans Cover AndroGel in Connecticut?

Most Connecticut commercial carriers, including Anthem Blue Cross Blue Shield of Connecticut, Cigna, Aetna, ConnectiCare, and Harvard Pilgrim Health Care, place AndroGel on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) of their formularies. Tier 3 copays in Connecticut typically run $50 to $90 per 30-day fill; Tier 4 copays can reach $100 to $150 or higher before deductible is met.

All major Connecticut carriers require prior authorization. Standard PA criteria mirror the Endocrine Society guideline [2]: two fasting morning serum testosterone values <300 ng/dL plus documented symptoms. Anthem's 2025 clinical criteria additionally require failure of or contraindication to one generic testosterone product (such as testosterone cypionate injection) before approving topical gel. Cigna does not mandate a step-therapy trial for gel in all circumstances, but does require laboratory confirmation and an ICD-10 diagnosis code of E29.1 (testicular hypofunction).

The FDA label for AndroGel specifies that dosing should be individualized based on serum testosterone measured approximately 14 days after starting therapy, which insurers may request as proof of therapeutic response when renewing coverage [4].

Open-enrollment periods on Connecticut's Access Health CT marketplace are the optimal time to compare formulary tier placement across plans if testosterone replacement is a known ongoing cost. A plan with a higher monthly premium but a lower specialty tier may save hundreds of dollars annually on AndroGel alone.

Is Compounded Testosterone Gel Legal in Connecticut?

Yes. Compounded testosterone gel dispensed by a state-licensed 503A pharmacy is legal in Connecticut when prepared for an individual patient with a valid prescription from a licensed prescriber [3]. Connecticut's Department of Consumer Protection, Drug Control Division, regulates 503A compounding pharmacies under both state pharmacy law and federal guidelines established by the Drug Quality and Security Act of 2013.

A 503A pharmacy may not manufacture testosterone gel in large batches for office use or resale, and may only prepare compounds when a patient-specific prescription exists. The compounded product is not FDA-approved and therefore carries no FDA-reviewed efficacy or safety labeling, but the active pharmaceutical ingredient (testosterone USP) must meet United States Pharmacopeia standards for purity and potency [3].

Compounded testosterone gel typically costs $80 to $120 per month at Connecticut 503A pharmacies, compared to the $510 list price for brand-name AndroGel. That price difference of roughly $390 per month represents $4,680 per year in potential savings for a cash-paying patient.

The T-Trials, a coordinated set of seven placebo-controlled trials (N=790 men, average age 72) published in the New England Journal of Medicine, found that testosterone gel (targeting serum testosterone of 500 to 750 ng/dL) produced statistically significant improvements in sexual function and bone mineral density compared to placebo, though cardiovascular outcomes were not significantly different at one year [5]. The trials used a commercial gel formulation, but the pharmacokinetics of compounded testosterone gel at equivalent doses are comparable when prepared to USP standards.

One practical caution: compounded testosterone gel cannot be billed to most insurance plans, so it functions exclusively as a cash-pay option. Patients using Connecticut Medicaid cannot typically access compounded testosterone as a covered benefit unless a medical necessity exception is granted.

How Does the AbbVie Savings Card Work in Connecticut?

AbbVie offers two patient assistance pathways for AndroGel: the myAbbVie Assist savings card for commercially insured patients and the full myAbbVie Assist Patient Assistance Program for uninsured or underinsured patients who meet income criteria.

Commercially insured Connecticut patients with private insurance (not Medicaid or Medicare) may use the myAbbVie Assist savings card to pay as little as $0 per month copay, subject to a per-year cap that AbbVie adjusts annually. In 2025, the program capped savings at $3,600 per year per patient. Patients enroll at abbvie.com/myabbvieassist or by calling 1-800-222-6885. The card is valid at most Connecticut retail pharmacies, including CVS and Walgreens, and at mail-order pharmacies in the state.

For patients without any insurance coverage, the myAbbVie Assist Patient Assistance Program may supply AndroGel at no cost for those with household incomes at or below 400% of the federal poverty level. Documentation required includes proof of income (tax returns or pay stubs), proof of Connecticut residency, and a completed prescriber enrollment form.

Medicare Part D patients in Connecticut are not eligible for manufacturer savings cards under federal anti-kickback rules. Medicare beneficiaries should instead explore the Extra Help (Low Income Subsidy) program through the Social Security Administration, which can reduce Part D drug costs to as little as $4.50 for generic drugs and $11.20 for brand-name drugs per fill in 2025 [6].

What Are the Cheapest Ways to Get Testosterone Gel in Connecticut?

The most affordable routes for testosterone replacement in Connecticut, ranked roughly by cost:

Compounded testosterone gel from a 503A pharmacy: $80 to $120 per month. This requires a valid prescription from a Connecticut-licensed provider and cannot be covered by insurance. The prescriber must specify concentration, volume, and instructions. A common formulation is testosterone 10 mg/mL or 50 mg/2.5 g application in a transdermal base.

Generic testosterone gel 1% (Vogelxo, Testim generics): $60 to $180 per month with GoodRx. Several generic topical testosterone gels have entered the US market since 2015. These are FDA-approved products and can be covered by insurance under the same prior authorization criteria as AndroGel [4]. Switching from branded AndroGel to a generic testosterone gel is the most straightforward way to cut costs while maintaining an FDA-regulated product.

AndroGel with AbbVie savings card: $0 to $60 per month for eligible commercially insured patients. This is the lowest-cost option for patients who have qualifying private insurance and do not use Medicare or Medicaid.

Connecticut Medicaid (HUSKY Health) with PA: $3 to $30 per month copay depending on formulary tier after prior authorization is granted.

Brand-name AndroGel cash price: ~$510 per month. This is the highest-cost option and is generally inadvisable without insurance or savings card enrollment.

The American Urological Association's 2018 guidelines on testosterone deficiency note that "testosterone therapy is effective at normalizing serum testosterone and improving symptoms of testosterone deficiency," and that clinicians should document baseline testosterone, hematocrit, prostate-specific antigen, and lipid values before initiating therapy [7]. All of these baseline labs should be obtained regardless of which product formulation is chosen.

How Is AndroGel Dosed and Monitored in Connecticut Clinical Practice?

AndroGel 1.62% is initiated at 40.5 mg (2 pump actuations) applied to the shoulders or upper arms once daily in the morning, after bathing. The FDA label permits titration to 20.25 mg (1 actuation) as the minimum or 81 mg (4 actuations) as the maximum based on serum testosterone drawn 2 to 8 hours after application, measured after at least 14 days on the current dose [4].

Serum testosterone target for most Connecticut TRT clinicians following Endocrine Society guidance is 400 to 700 ng/dL in the mid-normal range, avoiding supraphysiologic peaks associated with polycythemia and cardiovascular strain [2]. Hematocrit should be checked at 3 to 6 months after initiation, as testosterone increases erythropoiesis; values above 54% generally prompt dose reduction or temporary discontinuation [2].

Skin-to-skin transfer of testosterone to women and children is a real risk. The FDA added a black-box warning in 2009 requiring patients to wash hands after application and cover the application site [4]. Connecticut pediatric endocrinologists have documented cases of virilization in children exposed through household contact [8].

PSA should be measured at 3 to 6 months, then annually. Men with a PSA above 4.0 ng/mL or with a PSA rise greater than 1.4 ng/mL in any 12-month period should be referred for urological evaluation before continuing testosterone therapy [7].

Can I Get AndroGel via Telehealth in Connecticut?

Yes. Connecticut law permits telehealth prescribing of controlled substances under the state's Telehealth Act (CGS Section 19a-906), provided the prescriber holds a valid Connecticut DEA registration and has conducted a clinical evaluation adequate to establish a diagnosis. Testosterone is a Schedule III controlled substance federally, so prescribers must hold both a federal DEA registration and, for Connecticut patients, be licensed by the Connecticut Medical Examining Board or relevant prescriber board.

Federal rules established during the COVID-19 public health emergency temporarily permitted prescribing of Schedule III through V controlled substances via audio-only or video telehealth without an in-person visit. The DEA has proposed making some of these flexibilities permanent through a Special Registration framework, though final rules had not been issued as of mid-2025 [9]. Connecticut providers should confirm their specific telehealth prescribing authority for Schedule III substances with their malpractice carrier and state licensing board.

Telehealth platforms operating in Connecticut, including HealthRX, typically require patients to obtain baseline labs (morning serum testosterone, LH, FSH, CBC, PSA, metabolic panel) at a local Connecticut draw site before an AndroGel prescription is issued. Follow-up serum testosterone monitoring at 6 to 8 weeks is standard practice to confirm therapeutic response and guide dose titration [2].

Connecticut-Specific Cost Decision Framework for Testosterone Gel in 2026

Choosing the right testosterone gel product in Connecticut depends on insurance status, income, and clinical history. The following framework reflects current Connecticut formulary data and state pharmacy law:

Step 1. Confirm the diagnosis. Two morning fasting serum testosterone values <300 ng/dL plus documented symptoms are required by Connecticut Medicaid, most private insurers, and good clinical practice. The Endocrine Society guideline [2] is the controlling document for this threshold.

Step 2. Check insurance formulary. Log in to your insurer's portal or call member services to identify which testosterone gel products are on formulary and at what tier. Ask specifically about generic testosterone gel 1% before assuming AndroGel is the only covered option.

Step 3. Apply for the AbbVie savings card if commercially insured. For patients on private insurance, the myAbbVie Assist card can reduce cost to near zero. Enroll before the first fill.

Step 4. If on Connecticut Medicaid, submit prior authorization with complete documentation. Include two testosterone values, symptom documentation, ICD-10 E29.1, and the prescriber's NPI and DEA number. Approval typically takes 3 to 10 business days.

Step 5. If uninsured or underinsured, evaluate compounded testosterone gel. Contact a Connecticut 503A pharmacy for pricing. Expect $80 to $120 per month for a compounded 1% testosterone gel (50 mg per 5 g application). Confirm the pharmacy's CT DCP license number before filling.

Step 6. If on Medicare Part D, apply for Extra Help. Manufacturer savings cards are not permitted. Extra Help can reduce Part D cost-sharing substantially [6].

A 2023 analysis published in JAMA Internal Medicine found that patients who used manufacturer copay assistance cards for hormone-related therapies had 34% higher medication adherence at 12 months compared to patients paying full out-of-pocket costs [10]. Adherence matters clinically: testosterone gel takes 3 to 6 months of consistent daily use to produce measurable improvements in bone mineral density and sexual function, as the T-Trials data confirmed [5].

Safety Considerations That Affect Insurance Coverage Decisions

Connecticut insurers and Medicaid periodically audit testosterone prescribing for appropriateness. Prescriptions issued without documented lab confirmation, or for indications not recognized by the FDA label (such as age-related decline without frank hypogonadism), may be reversed or denied on retrospective review.

The FDA label explicitly states AndroGel is approved only for males with primary or secondary hypogonadism confirmed by laboratory testing, and is not approved for use in women [4]. Connecticut Medicaid has clawed back pharmacy payments in cases where AndroGel was dispensed without a qualifying ICD-10 code on file.

Cardiovascular safety of testosterone therapy remains an area of active research. The TRAVERSE trial (N=5,246, median follow-up 33 months), published in the New England Journal of Medicine in 2023, found that testosterone replacement in middle-aged and older men with hypogonadism did not increase major adverse cardiovascular events compared to placebo, with a hazard ratio of 0.96 (95% CI 0.83 to 1.12) [11]. The FDA reviewed these data and updated prescribing guidance accordingly in 2024. Knowing this trial exists and its outcome is useful when discussing therapy continuation with insurers who had previously imposed cardiovascular risk-based coverage restrictions.

The Endocrine Society notes that testosterone therapy is contraindicated in men with a hematocrit above 54%, untreated severe obstructive sleep apnea, uncontrolled heart failure, a PSA above 4.0 ng/mL without urological evaluation, or active desire for fertility [2]. These contraindications affect both clinical eligibility and insurance authorization status in Connecticut.